PL449370A1 - Nowe pochodne N-terfenylopikolinamidu oraz ich zastosowanie - Google Patents

Nowe pochodne N-terfenylopikolinamidu oraz ich zastosowanie

Info

Publication number
PL449370A1
PL449370A1 PL449370A PL44937024A PL449370A1 PL 449370 A1 PL449370 A1 PL 449370A1 PL 449370 A PL449370 A PL 449370A PL 44937024 A PL44937024 A PL 44937024A PL 449370 A1 PL449370 A1 PL 449370A1
Authority
PL
Poland
Prior art keywords
terphenylpicolinamide
derivatives
new
application
pathway
Prior art date
Application number
PL449370A
Other languages
English (en)
Inventor
Damian Muszak
Łukasz Skalniak
Julia ZĄBER
Oskar Kruc
Ewa Surmiak
Original Assignee
Uniwersytet Jagielloński
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński filed Critical Uniwersytet Jagielloński
Priority to PL449370A priority Critical patent/PL449370A1/pl
Priority to PCT/PL2025/050062 priority patent/WO2026024198A1/en
Publication of PL449370A1 publication Critical patent/PL449370A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pyridine Compounds (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Ujawniono nowe pochodne N-terfenylopikolinamidu stanowiące małocząsteczkowe inhibitory szlaku PD-1/PD-L1, będącego kluczowym punktem kontroli odpowiedzi immunologicznej, mogące znaleźć zastosowanie w immunoterapii nowotworów.
PL449370A 2024-07-26 2024-07-26 Nowe pochodne N-terfenylopikolinamidu oraz ich zastosowanie PL449370A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL449370A PL449370A1 (pl) 2024-07-26 2024-07-26 Nowe pochodne N-terfenylopikolinamidu oraz ich zastosowanie
PCT/PL2025/050062 WO2026024198A1 (en) 2024-07-26 2025-07-26 Novel n-terphenylpicolinamide derivatives and their use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL449370A PL449370A1 (pl) 2024-07-26 2024-07-26 Nowe pochodne N-terfenylopikolinamidu oraz ich zastosowanie

Publications (1)

Publication Number Publication Date
PL449370A1 true PL449370A1 (pl) 2026-02-02

Family

ID=98565906

Family Applications (1)

Application Number Title Priority Date Filing Date
PL449370A PL449370A1 (pl) 2024-07-26 2024-07-26 Nowe pochodne N-terfenylopikolinamidu oraz ich zastosowanie

Country Status (2)

Country Link
PL (1) PL449370A1 (pl)
WO (1) WO2026024198A1 (pl)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11266643B2 (en) * 2019-05-15 2022-03-08 Chemocentryx, Inc. Triaryl compounds for treatment of PD-L1 diseases
WO2022152316A1 (zh) * 2021-01-18 2022-07-21 南京明德新药研发有限公司 联苯衍生物及其应用
PL439107A1 (pl) * 2021-09-30 2023-04-03 Recepton Spółka Z Ograniczoną Odpowiedzialnością Podstawione pochodne 1,1´-bifenylu w połączeniu z aminokwasami i dipeptydami do stosowania w immunoterapii nowotworów

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11266643B2 (en) * 2019-05-15 2022-03-08 Chemocentryx, Inc. Triaryl compounds for treatment of PD-L1 diseases
WO2022152316A1 (zh) * 2021-01-18 2022-07-21 南京明德新药研发有限公司 联苯衍生物及其应用
PL439107A1 (pl) * 2021-09-30 2023-04-03 Recepton Spółka Z Ograniczoną Odpowiedzialnością Podstawione pochodne 1,1´-bifenylu w połączeniu z aminokwasami i dipeptydami do stosowania w immunoterapii nowotworów

Also Published As

Publication number Publication date
WO2026024198A1 (en) 2026-01-29

Similar Documents

Publication Publication Date Title
EP4470609A3 (en) Pcsk9 inhibitors and methods of use thereof
EP4026835A3 (en) Pd-1/pd-l1 inhibitors
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
EP4234030A3 (en) Pd-1/pd-l1 inhibitors
MX2021009562A (es) Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1.
PH12021500005A1 (en) Sulfonimidamide compounds as inhibitors of interleukin-1 activity
AU2021280113A8 (en) Pyrimidine compound as AXL inhibitor
JOP20200288A1 (ar) مشتقات تترا هيدرو – إيميدازو[4، 5-c]بيريدين كمعدِّلات مناعية pd-l1
EP4249000A3 (en) Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
WO2020243415A3 (en) Tead inhibitors and uses thereof
MX382562B (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub).
AU2017266951A1 (en) Use of Glutamate modulating agents with Immunotherapies to treat cancer
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
MX2022012471A (es) Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.
EP3943083A4 (en) SMALL MOLECULE PD-1/PD-L1 INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF WITH PD-L1 ANTIBODY, AND USES THEREOF
EP4541352A3 (en) Compositions and methods for treating non-alcoholic steatohepatitis
WO2024026483A3 (en) Cdk2 inhibitors and methods of using the same
WO2024026479A3 (en) Cdk2 inhibitors and methods of using the same
WO2024026486A3 (en) Cdk2 inhibitors and methods of using the same
MX2024014079A (es) Inhibidores de la proteina cinasa activada por mitogeno (mek) y usos de estos
EP4559526A3 (en) Composition for regulating cancer cell division or differentiation comprising setdb1 or a setdb1 inhibitor
PL449370A1 (pl) Nowe pochodne N-terfenylopikolinamidu oraz ich zastosowanie
WO2021046634A8 (en) Methods of treating cancer by the use of pd-1 axis inhibitors and anti-periostin antibodies
PL439107A1 (pl) Podstawione pochodne 1,1´-bifenylu w połączeniu z aminokwasami i dipeptydami do stosowania w immunoterapii nowotworów
WO2021138331A3 (en) Small molecule inhibitors of ulk1